Phase 1b/2a diSArm trial evaluated AP-SA02 as a potential treatment for complicated Staphylococcus aureus bacteremia Topline data anticipated in Q2 2025 to support potential future pivotal bacteremia efficacy trialLOS ANGELES, May 1, 2025 /PRNewswire/ -- Armata Pharmaceuticals, Inc. (NYSE American: ARMP) ("Armata" or the "Company"), a biotechnology company focused on the development of high-purity, pathogen-specific bacteriophage therapeutics for the treatment of antibiotic-resistant and difficult-to-treat ...

Group 1: Century Communities (CCS) - Century Communities is a home building and construction company operating in major metropolitan markets in Colorado, Texas, and Nevada [1] - The Zacks Consensus Estimate for its current year earnings has been revised 20.5% downward over the last 60 days [1] Group 2: Armata Pharmaceuticals (ARMP) - Armata Pharmaceuticals is a biotechnology company focused on developing bacteriophage therapeutics for antibiotic-resistant infections using proprietary technology [2] - The Zacks Consensus Estimate for its current year earnings has been revised almost 14.1% downward over the last 60 days [2] Group 3: Cable One (CABO) - Cable One is a cable company providing internet, cable television, and telephone services primarily in the United States [3] - The Zacks Consensus Estimate for its current year earnings has been revised 8.5% downward over the last 60 days [3]

Core Insights - Armata Pharmaceuticals reported significant clinical milestones and financial results for Q4 and full-year 2024, focusing on its bacteriophage therapeutics for antibiotic-resistant infections [1] Clinical Developments - The company achieved encouraging topline results from its Phase 2 Tailwind study for inhaled AP-PA02 in non-cystic fibrosis bronchiectasis (NCFB) patients, demonstrating a statistically significant reduction in Pseudomonas aeruginosa (P.a.) colony forming units (CFUs) [3][4] - AP-PA02 was well-tolerated, with mild and self-limiting treatment-emergent adverse events, and showed effectiveness comparable to antibiotic combination therapy [4] - Enrollment was completed for the Phase 1b/2a diSArm study evaluating AP-SA02 for Staphylococcus aureus bacteremia, with topline results expected in the first half of 2025 [3][4] Financial Performance - Grant revenue for Q4 2024 was $1.2 million, down from $1.5 million in Q4 2023, reflecting MTEC's share of costs for the AP-SA02 program [6] - Research and development expenses increased to approximately $8.5 million in Q4 2024 from $7.9 million in Q4 2023, indicating continued investment in clinical programs [7] - General and administrative expenses rose slightly to approximately $3.3 million in Q4 2024 from $3.2 million in Q4 2023, primarily due to increased personnel costs [8] Operational Loss and Net Income - The company reported a loss from operations of approximately $10.5 million in Q4 2024, compared to a loss of approximately $9.6 million in Q4 2023 [9] - Net income for Q4 2024 was $2.6 million, or $0.07 per share, contrasting with a net loss of $19.8 million, or $(0.55) per share, in Q4 2023, largely due to non-cash gains from changes in fair value of convertible loans [10] Cash Position - As of December 31, 2024, Armata held approximately $14.8 million in cash and cash equivalents, down from $19.2 million a year earlier [11] - The company entered into a $10 million secured credit agreement with Innoviva, with an annual interest rate of 14% [12] Strategic Focus - Armata remains committed to developing phage therapy as an alternative to broad-spectrum antibiotics, aiming to address the global health crisis of antimicrobial resistance [5]

Core Insights - Armata Pharmaceuticals, Inc. is a clinical-stage biotechnology company focused on developing high-purity pathogen-specific bacteriophage therapeutics to treat antibiotic-resistant and difficult-to-treat bacterial infections [1][2] - The company is advancing a broad pipeline of natural and synthetic phage candidates targeting pathogens such as Pseudomonas aeruginosa and Staphylococcus aureus [2] Company Overview - Armata Pharmaceuticals utilizes proprietary bacteriophage-based technology for its therapeutic developments [2] - The company has in-house phage-specific cGMP manufacturing capabilities to support full commercialization of its products [2] Upcoming Events - Dr. Deborah Birx, the CEO of Armata, will present at the 7th Annual Bacteriophage Therapy Summit on March 13, 2025, in Boston, MA [1]

Results demonstrate that inhaled AP-PA02 provides a durable reduction of Pseudomonas aeruginosa in the lung, with a favorable safety and tolerability profile LOS ANGELES, Dec. 19, 2024 /PRNewswire/ -- Armata Pharmaceuticals, Inc. (NYSE American: ARMP) ("Armata" or the "Company"), a biotechnology company focused on the development of high-purity pathogen-specific bacteriophage therapeutics for chronic pulmonary diseases and antibiotic-resistant bacterial pathogens, today announced encouraging topline result ...

LOS ANGELES, Nov. 19, 2024 /PRNewswire/ -- Armata Pharmaceuticals, Inc. (NYSE American: ARMP) ("Armata" or the "Company"), a clinical-stage biotechnology company focused on pathogen-specific bacteriophage therapeutics for antibiotic-resistant and difficult-to-treat bacterial infections, today announced that Dr. Deborah Birx, Chief Executive Officer, will deliver a presentation at 1:15pm ET at the 5th Annual Phage Futures Annual Meeting, which is being held November 19th in Boston, MA.For more information: h ...

Group 1 - Armata Pharmaceuticals reported a quarterly loss of $0.15 per share, better than the Zacks Consensus Estimate of a loss of $0.28, and an improvement from a loss of $0.31 per share a year ago, resulting in an earnings surprise of 46.43% [1] - The company posted revenues of $2.97 million for the quarter ended September 2024, exceeding the Zacks Consensus Estimate by 230.33%, compared to revenues of $1.23 million in the same quarter last year [2] - Armata Pharmaceuticals has surpassed consensus revenue estimates two times over the last four quarters [2] Group 2 - The stock has underperformed, losing about 15.1% since the beginning of the year, while the S&P 500 has gained 25.5% [3] - The current consensus EPS estimate for the coming quarter is -$0.29 on revenues of $1.13 million, and for the current fiscal year, it is -$1.02 on revenues of $3 million [7] - The Zacks Industry Rank for Medical - Biomedical and Genetics is in the top 26% of over 250 Zacks industries, indicating a favorable outlook for the industry [8]

Core Insights - Armata Pharmaceuticals reported financial results for Q3 2024, highlighting advancements in its bacteriophage therapeutic programs and financial performance improvements [1][2][3]. Clinical Developments - Enrollment for the Phase 2 "Tailwind" study of inhaled AP-PA02 in patients with non-cystic fibrosis bronchiectasis and chronic pulmonary Pseudomonas aeruginosa infection has been completed, with topline data expected by year-end [2][3]. - The company is preparing to initiate a pivotal bronchiectasis trial in 2025 for chronic pulmonary P. aeruginosa infection [2][3]. - Enrollment for the Phase 1b/2a "diSArm" study of intravenous AP-SA02 in patients with Staphylococcus aureus bacteremia has also been completed, with topline data anticipated in Q1 2025 [2][3]. - The company plans to meet with the U.S. FDA to align on the design of a pivotal Phase 3 bronchiectasis study for inhaled AP-PA02 [3]. Financial Performance - Grant revenue for Q3 2024 was $3.0 million, up from $1.2 million in Q3 2023, reflecting support for the AP-SA02 program [4]. - Research and development expenses increased to approximately $9.5 million in Q3 2024 from approximately $8.0 million in Q3 2023, indicating continued investment in clinical programs [5]. - General and administrative expenses decreased to approximately $3.2 million in Q3 2024 from approximately $3.6 million in Q3 2023, primarily due to reduced professional services costs [6]. - The loss from operations for Q3 2024 was approximately $9.8 million, an improvement from a loss of approximately $10.3 million in Q3 2023 [7]. - The net loss for Q3 2024 was $5.5 million, or $0.15 per share, compared to a net loss of $31.2 million, or $0.86 per share, in Q3 2023 [8]. Cash Position - As of September 30, 2024, the company held approximately $17.1 million in unrestricted cash and cash equivalents, an increase from $13.5 million as of December 31, 2023 [9].

Core Insights - Armata Pharmaceuticals has completed enrollment for its Phase 1b/2a diSArm study of intravenous AP-SA02, targeting Staphylococcus aureus bacteremia, with topline data expected in Q1 2025 [1][2] - The study aims to evaluate the safety and efficacy of AP-SA02 as a treatment option for patients suffering from serious bloodstream infections resistant to conventional antibiotics [2][3] Enrollment and Study Design - The diSArm study has enrolled 50 participants, marking a significant milestone in the development of AP-SA02 [1][2] - The study is designed as a randomized, double-blind, placebo-controlled trial, assessing the safety, tolerability, and efficacy of AP-SA02 in conjunction with best available antibiotic therapy [5] Clinical Safety and Efficacy - During the Phase 2a portion, Armata focused on the clinical safety of higher intravenous doses of AP-SA02, achieving dose escalation to 5E10 PFU every six hours without significant adverse events [2] - Two distinct subsets of subjects have shown evidence of phage persistence in the blood, indicating potential in vivo phage amplification [2] Future Plans and Regulatory Engagement - Armata plans to initiate a pivotal bacteremia efficacy study later in 2025, contingent on positive topline data [2][3] - The company intends to discuss the pivotal trial design with the U.S. Food and Drug Administration [3] Financial Support - The clinical development of AP-SA02 is partially funded by $21.6 million from the Defense Health Agency and Joint Warfighter Medical Research Program [4]

Core Insights - Armata Pharmaceuticals has published a paper detailing the structure of phage Pa193, a key candidate for its multi-phage anti-Pseudomonas clinical products [1][2] - The research enhances understanding of phage structure and function, potentially expanding clinical applications beyond Pseudomonas aeruginosa [3] Company Overview - Armata Pharmaceuticals is a clinical-stage biotechnology company focused on developing pathogen-specific bacteriophage therapeutics for antibiotic-resistant bacterial infections [4] - The company is advancing a pipeline of natural and synthetic phage candidates targeting various pathogens, including Pseudomonas aeruginosa and Staphylococcus aureus [4]